
Interim data reveals potential of new pancreatic cancer drug
Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma. Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The… Read More

